Johnson MR - Search Results

1

Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.

Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB. Saif MW, et al. Among authors: johnson mr. Cancer J. 2007 Jul-Aug;13(4):247-56. doi: 10.1097/PPO.0b013e31813c12b8. Cancer J. 2007. PMID: 17762760 Clinical Trial.

2

Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.

Saif MW, Black G, Johnson M, Russo S, Diasio R. Saif MW, et al. Cancer Chemother Pharmacol. 2006 Dec;58(6):771-5. doi: 10.1007/s00280-006-0223-8. Epub 2006 Mar 22. Cancer Chemother Pharmacol. 2006. PMID: 16552574

3

Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.

Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR. Saif MW, et al. Among authors: johnson mr. J Clin Oncol. 2005 Dec 1;23(34):8679-87. doi: 10.1200/JCO.2005.02.0628. J Clin Oncol. 2005. PMID: 16314628 Clinical Trial.

4

Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?

Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB. Saif MW, et al. Among authors: johnson mr. Support Cancer Ther. 2007 Sep 1;4(4):211-8. doi: 10.3816/SCT.2007.n.017. Support Cancer Ther. 2007. PMID: 18632519

5

Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?

Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M. Saif MW, et al. JOP. 2007 Nov 9;8(6):799-805. JOP. 2007. PMID: 17993734

6

Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.

Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Blanquicett C, et al. Among authors: johnson mr. Mol Cancer Ther. 2002 Oct;1(12):1139-45. Mol Cancer Ther. 2002. PMID: 12481438

7

Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.

Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR. Blanquicett C, et al. Among authors: johnson mr. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8773-81. doi: 10.1158/1078-0432.CCR-05-0627. Clin Cancer Res. 2005. PMID: 16361565

8

The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.

Diasio RB, Johnson MR. Diasio RB, et al. Among authors: johnson mr. Pharmacology. 2000 Sep;61(3):199-203. doi: 10.1159/000028401. Pharmacology. 2000. PMID: 10971206 Review.

9

Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.

Diasio RB, Johnson MR. Diasio RB, et al. Among authors: johnson mr. Clin Cancer Res. 1999 Oct;5(10):2672-3. Clin Cancer Res. 1999. PMID: 10537327 No abstract available.

10

Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.

Johnson MR, Diasio RB. Johnson MR, et al. Adv Enzyme Regul. 2001;41:151-7. doi: 10.1016/s0065-2571(00)00011-x. Adv Enzyme Regul. 2001. PMID: 11384742 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

993 results

Search Page

Filters